Device Trial Radar · NCT04701931
OCT Angiography Software Evaluation Study
Last checked: Nov 19, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Jan 7, 2021
Primary completion
Nov 9, 2022
Study completion Jun 6, 2023
Sponsor
- Lead sponsor
- Topcon CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 8, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Comparisons for vascular structure visualization in the retina and choroid.
Conditions
- Retina Condition Followed by Fluorescein Angiography Imaging
Interventions
Maestro2 OCTADevice
The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
Cirrus HD-OCT 5000Device
The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
TRC-50DXDevice
The TRC-50DX retinal camera images the fundus used for diagnostic purposes
Primary outcomes
What the sponsor says the trial is designed to measure.
- OCTA image qualityTime frame: Day 1
- Visibility of key anatomical vascular featuresTime frame: Day 1
- Identification of key pathological vascular featuresTime frame: Day 1
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Orange County Retina Medical Group
Santa Ana, California
Southeast Retina Center
Augusta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.